IIQ released their slides for tomorrow's presentation (18 April 2024 at 11am).
https://www.inoviq.com/site/pdf/6e5c1044-23c2-4388-b0ed-7bbbe1660dbf/INOVIQ-Investor-Update.pdf
I don't see much new news. BUT
Reading between the lines/slides.....i def think they have been using this slide pack to present to institutions for the impending capital raise.
The following slides are new:
Slide 3 - This is their "Snap shot" slide up front. For the boss to look at in a fund before signing off.
Slide 5 - This explains the IIQ journey....very typical when explaining to and institution that has no background knowledge.
Slide 26 & 27 - Shows to the institution how similar deals have played out (Therapeutic and diagnostic).
So things are def happening in the background.
I have also sent an email to David Williams with some questions I was hoping he could answer during the webinar (note the numbering I sent him was correct...the copy and paste below has lost the number order):
- How did you come across IIQ (Sienna/Bard1)?
- What is your vision for IIQ?
- Why are the IIQ products better than the current products in the market and its competitors?
- SubB2M
- Exo-Net
- Exosome tests
- Exosome therapeutics
- Why can’t SubB2M be used for both screening and monitoring? The screening market for asymptomatic people is the bigger market?
- The names for IIQs products are quite technical and confusing. Has any thought been given to a marketing strategy?
- When will the IIQ website be updated? It seems to have not been updated in a while. And it is confusing for new potential investors.
- Have you got the right commercial strategy for the Exo-Net product? I believe that when a researcher uses the product, they agree to IIQ having a percentage share of any exosome technology that is developed. Is this preventing its adoption in the research community?
- What is the ‘approach to market/sales strategy’ in the diagnostic market? Do you employ sales people to visit doctors? Or is the key to get the pathology labs signed up?
- You spoke at the Nov 2023 AGM where you were voted in as Chairman of IIQ, about the likelihood of a “large” capital raise to accelerate commercialisation. You did a similar capital raise for PNV. What learnings can you apply to IIQ?
- Focus on the USA first?
- Build sales teams or use distributors?
- Acquisitions?
- Dr Leearne has done a great job with the scientific development of the IIQ products. But with Commercialisation being a large focus, will there be any changes in the leadership structure?